Skip to main navigation Skip to search Skip to main content

Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial

  • Jan C. Koch
  • , Andreas Leha
  • , Helen Bidner
  • , Isabell Cordts
  • , Johannes Dorst
  • , René Günther
  • , Daniel Zeller
  • , Nathalie Braun
  • , Moritz Metelmann
  • , Philippe Corcia
  • , Elisa De La Cruz
  • , Patrick Weydt
  • , Thomas Meyer
  • , Julian Großkreutz
  • , Marie Hélène Soriani
  • , Shahram Attarian
  • , Jochen H. Weishaupt
  • , Ute Weyen
  • , Josua Kuttler
  • , Gabriela Zurek
    • Mary Louise Rogers, Emily Feneberg, Marcus Deschauer, Christoph Neuwirth, Joanne Wuu, Albert C. Ludolph, Jens Schmidt, Yvonne Remane, William Camu, Tim Friede, Michael Benatar, Markus Weber, Paul Lingor, ROCK-ALS Study group, Danielle Renfrey

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)
26 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry